X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB ASTRAZENECA PHARMA UNICHEM LAB/
ASTRAZENECA PHARMA
 
P/E (TTM) x -64.6 160.8 - View Chart
P/BV x 0.7 25.0 2.9% View Chart
Dividend Yield % 2.3 0.0 -  

Financials

 UNICHEM LAB   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
ASTRAZENECA PHARMA
Mar-14
UNICHEM LAB/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3821,285 29.7%   
Low Rs234634 36.9%   
Sales per share (Unadj.) Rs116.3189.6 61.3%  
Earnings per share (Unadj.) Rs-18.9-0.2 9,293.3%  
Cash flow per share (Unadj.) Rs-11.73.8 -305.4%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.60-  
Book value per share (Unadj.) Rs381.068.6 555.1%  
Shares outstanding (eoy) m70.3425.00 281.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.65.1 52.3%   
Avg P/E ratio x-16.3-4,712.7 0.3%  
P/CF ratio (eoy) x-26.2249.6 -10.5%  
Price / Book Value ratio x0.814.0 5.8%  
Dividend payout %-26.40-   
Avg Mkt Cap Rs m21,66823,988 90.3%   
No. of employees `0002.31.6 146.2%   
Total wages/salary Rs m2,0061,605 125.0%   
Avg. sales/employee Rs Th3,587.83,040.2 118.0%   
Avg. wages/employee Rs Th880.01,029.2 85.5%   
Avg. net profit/employee Rs Th-583.7-3.3 17,879.1%   
INCOME DATA
Net Sales Rs m8,1804,740 172.6%  
Other income Rs m61092 662.4%   
Total revenues Rs m8,7904,832 181.9%   
Gross profit Rs m-1,320-130 1,017.1%  
Depreciation Rs m505101 499.1%   
Interest Rs m800-   
Profit before tax Rs m-1,295-139 932.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m335 656.6%   
Profit after tax Rs m-1,331-5 26,147.7%  
Gross profit margin %-16.1-2.7 589.3%  
Effective tax rate %-2.6-3.7 70.4%   
Net profit margin %-16.3-0.1 15,150.5%  
BALANCE SHEET DATA
Current assets Rs m23,3182,726 855.3%   
Current liabilities Rs m4,6352,435 190.4%   
Net working cap to sales %228.46.1 3,714.8%  
Current ratio x5.01.1 449.3%  
Inventory Days Days12274 165.1%  
Debtors Days Days12141 298.0%  
Net fixed assets Rs m8,1631,035 788.5%   
Share capital Rs m14150 281.4%   
"Free" reserves Rs m26,660942 2,829.0%   
Net worth Rs m26,8011,716 1,561.8%   
Long term debt Rs m30-   
Total assets Rs m31,8904,156 767.3%  
Interest coverage x-15.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.31.1 22.5%   
Return on assets %-3.9-0.1 3,202.6%  
Return on equity %-5.0-0.3 1,674.2%  
Return on capital %-4.50-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m4,356375 1,162.9%   
Fx outflow Rs m0470 0.0%   
Net fx Rs m4,356-96 -4,559.3%   
CASH FLOW
From Operations Rs m-1,123-8 13,869.1%  
From Investments Rs m16,487-146 -11,315.5%  
From Financial Activity Rs m-8,811862 -1,022.0%  
Net Cashflow Rs m6,552709 924.8%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 15.1 0.3 5,033.3%  
FIIs % 3.0 15.7 19.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 9.1 348.4%  
Shareholders   20,176 12,856 156.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare UNICHEM LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 19, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS